The diagnosis of treatment-resistant depression (TRD) is established when a patient with depression does not respond positively to two antidepressant treatments administered at appropriate dosages and durations (minimum of six to eight weeks).

SPRAVATO® ( Esketamine) is the only FDA-approved treatment used as monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression (MDD with inadequate response to at least 2 oral antidepressants of adequate dose and duration).

TRD Efficacy & Safety

Over 90,000 patients in the US have received treatment with SPRAVATO® as shown below in short-term (as early as 24 hours) and long-term (up to 5 years) studies.

Administration: Via Nasal Spray in a clinical setting. At least 2 hours of monitoring is required after administration.